Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kick Me...Please! -- Ignore unavailable to you. Want to Upgrade?

To: M CAHILL who wrote (9)	4/9/1999 12:42:00 AM
From: Mike McFarland	Respond to of 21

yeah Amgen probably is the biggest biotech, but I would not buy it right now. For instance, Amgen has a real profitable drug--Epogen, and yet, in a few years it will be possible for genetic therapy to induce EPO production right in the body (it can already be done, but clinical trials will take awhile). A fellow in a post to me once said 'why inject protiens when you can just induce gene therapy, and secrete'...or something like that. Freaky stuff, but is is happening--like I said, things change, and nothing will change faster than biotechnology. The question for me is whether or not I am clever enough to follow it all and make the right choices. Might as well try, could be fun--not a good bet, but I'm sure not going to "invest" in MSFT instead. Now kick!